Overview and Scope
Doxorubicin is a powerful chemotherapy medication that belongs to a class of drugs known as anthracyclines and works by interfering with the DNA and RNA synthesis in cancer cells, preventing their growth and division. It is used for the chemotherapy treatment of distinct types of cancer.
Sizing and Forecast
The doxorubicin market size has grown strongly in recent years. It will grow from $1.23 billion in 2023 to $1.32 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to chemotherapy advancements, oncology treatment standard, clinical efficacy, patient survival rates, physician recommendations.
The doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized medicine advancements, targeted drug delivery systems, immunotherapy combinations, genomic and biomarker research, precision oncology growth. Major trends in the forecast period include nanotechnology integration, combination therapies, biosimilar market expansion, adjuvant therapy focus, cardioprotective interventions.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/doxorubicin-global-market-report
The doxorubicin market covered in this report is segmented –
1) By Drug Formulation: Lyophilized Powder, Doxorubicin Injection
2) By Application: Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
North America was the largest region in the doxorubicin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=11974&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of cancer is driving the doxorubicin market forward. Cancer is a group of diseases in which cells grow abnormally and uncontrollably. Doxorubicin is a common antibiotic used in chemotherapy to treat distinct types of cancers, as it limits the growth of cancer cells by damaging their DNA. The growing incidence of cancer has led to a higher demand for doxorubicin. For instance, according to the 2021 American Cancer Society report, 1.8 million new cases of cancer diagnosed were diagnosed in 2020. Furthermore, according to September 2020 data published by the National Cancer Institute, a US-based government agency part of the National Institutes of Health, 1,806,590 new cancer cases were recorded, indicating that 43% of all cancer diagnosed in men in the United States in 2020, up from 1,752,735 in the previous year, i.e., 2019. Thus, the increasing prevalence of cancer patients is driving the doxorubicin market.
Key Industry Players
Major companies operating in the doxorubicin market report are Pfizer Inc., Johnson and Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Hospira Inc., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Mylan Pharmaceuticals Inc., VHB Life Sciences Limited, Xi’an International Healthcare Factory Co. Ltd., Accord Healthcare Ltd., TTY Biopharm Company Limited, Cadila Pharmaceuticals, Neon Laboratories Limited, APP Pharmaceuticals Manufacturing LLC, Sun Pharmaceutical Industries Ltd., Transo-Pharm Handels GmbH, LGM Pharma, Zhejiang Hisun Pharma, Actavis Pharma, Celon Laboratories Limited, Samarth Life Sciences Pvt. Ltd
The doxorubicin market report table of contents includes:
1. Executive Summary
2. Doxorubicin Characteristics
3. Doxorubicin Trends And Strategies
4. Doxorubicin – Macro Economic Scenario
5. Global Doxorubicin Size and Growth
…..
32. Global Doxorubicin Competitive Benchmarking
33. Global Doxorubicin Competitive Dashboard
34. Key Mergers And Acquisitions In The Doxorubicin
35. Doxorubicin Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
